U.S. Luxury Stock News

NasdaqGM:DOMO
NasdaqGM:DOMOSoftware

Domo (DOMO) Narrows Q3 Net Loss, Testing Bearish Profitability Narratives

Domo (DOMO) has just put Q3 2026 on the books with revenue of about $79.4 million and a basic EPS loss of roughly $0.25, keeping the focus firmly on how efficiently the business is converting its topline into sustainable earnings. The company has seen quarterly revenue hover in a tight band around $78 million to $80 million over the past six reported periods, while EPS has similarly stayed in negative territory between approximately $0.25 and $0.56 per share, underscoring that margins remain...
NYSE:HPE
NYSE:HPETech

Hewlett Packard Enterprise (HPE): TTM Net Loss Challenges Bullish Margin-Recovery Narrative

Hewlett Packard Enterprise (HPE) has wrapped up FY 2025 with fourth quarter revenue of $9.7 billion, Basic EPS of $0.11, and net income of $146 million, putting a spotlight on how its margins are holding up late in the fiscal year. The company has seen revenue move from $8.5 billion and Basic EPS of $1.02 in Q4 2024 to $9.7 billion and $0.11 in Q4 2025. Over the same period, trailing twelve month EPS has swung from $1.95 to slightly negative, setting up a nuanced debate around the trade off...
NasdaqGS:ULTA
NasdaqGS:ULTASpecialty Retail

Ulta Beauty (ULTA) Q3: 6.3% Comps Rebound Tests Margin-Squeeze Bear Narrative

Ulta Beauty (ULTA) just turned in another busy quarter, with Q3 2026 revenue of about $2.9 billion, basic EPS of $5.16, and net income of $230.9 million. This sets the stage for investors to recheck the trajectory of its beauty retail engine. The company has seen quarterly revenue move from $2.53 billion in Q3 2025 to $2.86 billion in Q3 2026 alongside EPS holding in the mid single digits. Trailing 12 month revenue has climbed to roughly $12.0 billion and EPS to $26.25, giving investors a...
NasdaqGS:SWBI
NasdaqGS:SWBILeisure

Smith & Wesson (SWBI) Q2: Thin 2.1% TTM Margin Tests Bullish Earnings Recovery Narrative

Smith & Wesson Brands (SWBI) has just posted a mixed Q2 2026 print, with revenue of about $124.7 million translating into basic EPS of roughly $0.04 on net income of $1.9 million. This sets a cautious tone around profitability. The company has seen quarterly revenue move from roughly $129.7 million in Q2 2025 to $124.7 million this quarter, while EPS has swung from $0.09 a year ago to a small profit after a loss of about $0.08 in Q1 2026, leaving investors watching whether margins can rebuild...
NYSE:IOT
NYSE:IOTSoftware

Samsara (IOT) Turns Q3 EPS Positive, Testing Bearish Valuation Narratives

Samsara (IOT) just posted Q3 2026 numbers with revenue of $416 million and Basic EPS of $0.01, marking a rare quarter in the black with net income of about $7.8 million. The company has seen revenue move from $300 million in Q2 2025 to $416 million in Q3 2026, while quarterly EPS shifted from a loss of about $0.09 to a modest profit as losses narrowed over time, and that margin progress is now front and center for investors dissecting this print. See our full analysis for Samsara. With the...
NasdaqGS:ZUMZ
NasdaqGS:ZUMZSpecialty Retail

Zumiez (ZUMZ) Q3: Profit Rebound Strengthens Bullish Margin-Recovery Narrative

Zumiez (ZUMZ) just posted a solid Q3 2026 print, with revenue of about $239 million and EPS of $0.57 as the specialty retailer continued to lean into its recent return to profitability. The company has seen revenue move from roughly $222 million in Q3 2025 to $239 million this quarter, while EPS climbed from $0.06 to $0.57, signaling a much healthier earnings run-rate as comparable sales rose 7.6% and margins pushed back into more comfortable territory for investors. See our full analysis for...
NasdaqGS:TTAN
NasdaqGS:TTANSoftware

ServiceTitan (TTAN) Q3 2026: Narrowing TTM Losses Challenge Bearish Profitability Narrative

Q3 2026 earnings snapshot and setup ServiceTitan (TTAN) just posted Q3 2026 results with revenue of about $249 million, a basic EPS loss of $0.42, and trailing twelve month revenue of roughly $916 million alongside a TTM EPS loss of $3.51. This underscores that the company is still in investment mode rather than profit harvesting. The business has seen revenue move from around $199 million in Q2 2025 to $249 million in Q3 2026 on a quarterly basis, and from roughly $685 million to $916...
NasdaqGM:RNA
NasdaqGM:RNABiotechs

Assessing Avidity Biosciences After Its 556.6% Surge and Bullish RNA Therapy Updates

Wondering if Avidity Biosciences is still a smart buy after its huge run, or if most of the upside is already priced in? Here is a look at what the numbers suggest about value from here. The stock has cooled slightly in the last week, slipping about 0.1%, but it is still up 2.6% over the past month, 129.7% year to date, and 556.6% over 3 years, which indicates the market has rapidly rewritten its expectations. That surge in optimism has been driven largely by excitement around Avidity's...
NYSE:HY
NYSE:HYMachinery

Is Hyster-Yale (HY) Using Dividends And Aftermarket Focus To Quietly Rewire Its Margin Story?

Hyster-Yale recently reported its latest quarterly results and declared a dividend, underscoring its ongoing role manufacturing and servicing lift trucks and components worldwide. The company’s emphasis on aftermarket services and operational performance highlights how it is trying to deepen recurring revenue streams within the industrial equipment sector. Next, we’ll examine how the quarterly earnings and dividend announcement interact with Hyster-Yale’s margin-improvement investment...
NasdaqGS:COO
NasdaqGS:COOMedical Equipment

Cooper Companies (COO) Margin Decline Tests Bullish 21% Earnings Growth Narrative

Cooper Companies (COO) just wrapped up FY 2025 with fourth quarter revenue of $1.1 billion and basic EPS of $0.43, capping a trailing twelve month run of $4.1 billion in revenue and $1.87 in EPS that investors will be dissecting closely. The company has seen revenue move from $3.9 billion and EPS of $1.97 over the twelve months to Q4 2024 to $4.1 billion and EPS of $1.87 over the latest twelve month period, setting a nuanced backdrop for how the current year’s performance fits into its longer...
NYSE:RBRK
NYSE:RBRKSoftware

Rubrik (RBRK) Q3: Rapid Revenue Growth Tests Bearish Profitability Narrative

Rubrik (RBRK) just posted its Q3 2026 scorecard, with quarterly revenue at about $309.9 million and basic EPS of roughly -$0.49, while trailing twelve month revenue sits near $1.1 billion against basic EPS of about -$2.34. The company has seen revenue move from $187.3 million and basic EPS of -$11.48 in early 2025 to $309.9 million and -$0.49 in the latest quarter, and about $679.5 million and -$16.19 on a trailing basis in early 2025 to $1.1 billion and -$2.34 today. This sets up a story of...
NYSE:ECG
NYSE:ECGConstruction

Is Everus Construction Group’s 2025 Valuation Justified After Its Strong 32.4% Rally?

If you are wondering whether Everus Construction Group is still a smart place to put fresh money to work, you are not alone. This stock has quickly become one value hunters are watching closely. After climbing an impressive 32.4% year to date and 33.7% over the last year, the share price has cooled slightly in the last month with a 1.6% pullback and is roughly flat over the past week at around $91.75. Recent moves have been driven less by headlines grabbing the front page and more by a...
NYSE:AGX
NYSE:AGXConstruction

Argan (AGX) Q3 2026: 81% TTM Earnings Surge Reinforces Bullish Profitability Narrative

Argan (AGX) has just posted its Q3 2026 scorecard, with revenue of about $251 million and basic EPS of $2.22, while trailing twelve month EPS sits at $8.76 on revenue of roughly $915 million as the business continues to scale. Over the past year, the company has seen net income climb from $66.11 million to $119.93 million on a trailing basis, and EPS step up from $4.94 to $8.76. This gives investors a cleaner read on how improving margins are feeding through to the bottom line. See our full...
NYSE:CHPT
NYSE:CHPTElectrical

ChargePoint (CHPT) Q3: Losses Narrow, Testing Bullish Profitability Narratives Despite Flat Revenue

ChargePoint Holdings (CHPT) just posted Q3 2026 results with revenue of about $105.7 million and a basic EPS loss of $2.23, while trailing 12 month figures show revenue of roughly $403.8 million against a basic EPS loss of $10.19. The company has seen quarterly revenue hover in a tight band between about $97.6 million and $108.5 million over the past six quarters, while basic EPS losses have consistently sat in the negative $2.2 to $3.6 range and TTM net income remains deeply in the red...
NasdaqCM:IMPP
NasdaqCM:IMPPOil and Gas

Imperial Petroleum (IMPP): Assessing Valuation After $60 Million Direct Offering of Stock and Warrants

Imperial Petroleum (IMPP) just moved to raise roughly $60 million through a registered direct offering of composite units, pairing common stock with warrants, a financing decision that can reshape both near term dilution and longer term upside. See our latest analysis for Imperial Petroleum. The financing news lands after a choppy stretch, with a roughly 30% 90 day share price return and about 59% one year total shareholder return suggesting momentum has been rebuilding despite recent...
NYSE:FIHL
NYSE:FIHLInsurance

Assessing Fidelis Insurance Holdings After Specialty Lines Expansion and Recent Share Price Pullback

If you are wondering whether Fidelis Insurance Holdings is a sleeper value play or a stock to avoid, you are in the right place. We are going to unpack what the current price is really telling us about the business. Despite a modest 0.6% gain year to date and a near flat 30 day move of 0.1%, the stock is still down 7.9% over the past year after a recent 5.0% pullback over the last week, which can leave investors unsure whether this is a buying opportunity or a warning sign. Recent news...
NYSE:FLNG
NYSE:FLNGOil and Gas

Is It Too Late To Consider FLEX LNG After A 480% Five Year Surge?

If you are wondering whether FLEX LNG still offers good value after its strong run, or if you might be late to the party, this breakdown can help you decide whether it deserves a spot on your radar. The stock is up 28.5% over the last year and 480.2% over five years. Year to date it is still rising 6.4%, despite a flat 0.4% over 30 days and a small 1.7% dip this week that may have caught value hunters’ attention. Recent trading has been driven more by shifting sentiment toward LNG shipping...
NasdaqGS:ABSI
NasdaqGS:ABSIBiotechs

Is Absci (ABSI) Using ABS-201 To Quietly Prove The Value Of Its AI Drug Engine?

Absci Corporation recently dosed the first healthy volunteers in its Phase 1/2a HEADLINE trial of ABS-201, an AI-designed anti-prolactin receptor antibody for androgenetic alopecia, with interim data planned for the second half of 2026. The company also aims to leverage safety and pharmacokinetic insights from this study to accelerate development of ABS-201 for endometriosis, potentially broadening the drug’s addressable patient population. Against this backdrop, we’ll examine how the...
NasdaqGS:HLIT
NasdaqGS:HLITCommunications

Has the Market Mispriced Harmonic After a 26.8% Drop in 2025?

Wondering if Harmonic at around $9.58 is a bargain or a value trap? You are not alone, and this is where a closer look at valuation really starts to matter. The stock has been choppy lately, up just 0.2% over the last week but still down 8.2% over the past month and 26.8% year to date. This hints that sentiment has cooled, even as the long term 5 year return of 36.7% tells a more optimistic story. Recently, investors have been weighing shifting expectations around Harmonic's broadband and...
NasdaqGS:WMT
NasdaqGS:WMTConsumer Retailing

Walmart (WMT) Net Margin Improvement Reinforces Bullish Profitability Narratives Despite Rich Valuation

Walmart (WMT) just posted its Q3 2026 numbers, with revenue of about $179.5 billion and net income of roughly $6.1 billion translating to EPS of $0.77 as investors focus on how these figures feed into the retailer’s earnings momentum story. The company has seen revenue move from around $169.6 billion in Q3 2025 to $179.5 billion in Q3 2026, while trailing twelve month net income climbed from about $19.4 billion to $22.9 billion. This sets the stage for investors to parse how sustained...
NasdaqGS:BDTX
NasdaqGS:BDTXBiotechs

Can Black Diamond Therapeutics’ (BDTX) Silevertinib CNS Data Redefine Its Precision Oncology Strategy?

Black Diamond Therapeutics recently reported topline Phase 2 data for silevertinib in first-line non-small cell lung cancer patients with non-classical EGFR mutations, and outlined plans to start a randomized Phase 2 trial in newly diagnosed glioblastoma in 2026. The early results, including strong central nervous system response rates and a broad range of EGFR alterations targeted, underscore silevertinib’s potential as a brain-penetrant precision therapy across multiple tumor types. We’ll...
NasdaqGS:SAIC
NasdaqGS:SAICProfessional Services

SAIC (SAIC) Q3 2026: Margin Expansion Reinforces Bullish Narrative Despite Revenue Pressure

Science Applications International (SAIC) opened Q3 2026 with Q2 revenue of about $1.8 billion and basic EPS of $2.72, setting the tone for another data heavy earnings season. The company has seen quarterly revenue move from $1.82 billion in Q2 2025 to $1.77 billion in Q2 2026, while EPS over that same span ranged from $1.59 to $2.72. This frames a period of shifting top line and per share results that investors will be watching closely. With trailing net profit margins now higher than a year...
NYSE:RERE
NYSE:RERESpecialty Retail

Three Stocks Estimated To Be Trading Below Intrinsic Value In December 2025

As the U.S. stock market experiences a modest uptick following key inflation data, major indices like the Dow Jones and S&P 500 are nearing all-time highs, reflecting investor optimism despite recent economic uncertainties. In this environment, identifying stocks that are trading below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervalued assets amid fluctuating market conditions.